Mucin in Sputum of CF During Pulmonary Exacerbation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00202072|
Recruitment Status : Unknown
Verified September 2005 by Philipps University Marburg Medical Center.
Recruitment status was: Recruiting
First Posted : September 20, 2005
Last Update Posted : September 20, 2005
|Condition or disease|
CF is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protective and clearance properties of the mucus gel. In a recent study we found that mucins are decreased in the sputum of adult CF patients.
In this study we want to investigate the differences on the mucin and DNA quantity and quality of airway secretions in during pulmoanry exacerbation.We hypothesize that during an exacerbation the mucin and DNA amount is increasing.
The aim of this study is to evaluate the molecular (mucins) and structure properties (mucin-DNA-network) of the airway secretions in CF related to the severity of the disease.
We characterize sputum composition of patients with pulmonary exacerbations. Using gel electrophoresis and dot-blot with specific antibodies we will analyze MUC5AC and MUC5B mucins. DNA amount will be measured by microfluorimetry. With the laser scanning confocal microscopy the mucin-DNA-network will be evaluated.
The significance of these studies is that they will give us novel information about the pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the progression of lung disease, and most critically, will identify novel opportunities and targets for therapeutic intervention.
|Study Type :||Observational|
|Enrollment :||25 participants|
|Observational Model:||Defined Population|
|Observational Model:||Natural History|
|Study Start Date :||January 2004|
|Study Completion Date :||September 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00202072
|Contact: Markus O Henke, MD||06421 ext firstname.lastname@example.org|
|Pediatric department, CF center, University Giessen||Recruiting|
|Contact: Hermann Lindemann, MD 0641/99 ext 43430 Hermann.Lindemann@paediat.med.uni-giessen.de|
|Pediatric department, CF center, University Marburg||Recruiting|
|Contact: Markus O Henke, MD 06421 ext 2866041 email@example.com|
|Principal Investigator:||Markus O Henke, MD||Philipps University Marburg Medical Center|